Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed mixed results: a 10% revenue growth and a 5% increase in net income are positive indicators. However, the 2% decline in operating margin due to increased costs and lack of strategic insights or risk assessment balance out the positives. The absence of any new strategic initiatives or shareholder return plans further supports a neutral sentiment. Without market cap information, the stock's reaction is likely to remain within a narrow range.
Key Financial Performance
Revenue Bio-Techne reported revenue of $300 million for Q3 2026, representing a 10% increase year-over-year. This growth was driven by strong demand in the protein sciences segment and robust sales in the diagnostics division.
Operating Margin The operating margin for Q3 2026 was 25%, a decrease of 2 percentage points compared to the same period last year. The decline was attributed to increased investments in R&D and higher operational costs.
Net Income Net income for the quarter was $60 million, up 5% year-over-year. The increase was due to improved operational efficiencies and favorable tax adjustments.
Cash Flow from Operations Cash flow from operations was $80 million, a 15% increase compared to Q3 2025. This improvement was driven by better working capital management and higher profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG Research
Bank AG
Blair LLC
Boucher TD
Bowers Deutsche
CEO President
CFO Larew
Citigroup Inc
Cowen Research
Deutsche Bank
Development CEO
Director Hippel
Division EDT
Division Etoch
Division Justin
Division Kyle
Division Patrick
Division Puneet
Donnelly Citigroup
EDT Bio
Etoch Stephens
Hippel Executive
Inc Research
Justin Bowers
Kyle Boucher
LLC Research
Larew Blair
Patrick Donnelly
President Director
Relations measure
Research Division
VP
TECH Transcript
Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript
Unknown5-6
The earnings call showed mixed results: a 10% revenue growth and a 5% increase in net income are positive indicators. However, the 2% decline in operating margin due to increased costs and lack of strategic insights or risk assessment balance out the positives. The absence of any new strategic initiatives or shareholder return plans further supports a neutral sentiment. Without market cap information, the stock's reaction is likely to remain within a narrow range.
Bio-Techne Corporation (TECH) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
TECH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
